Release date- 06082019 - A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints.

In addition, Dupixent comes in 200 mg and 300 mg doses in pre-filled syringe for adolescents with atopic dermatitis. It is intended for injection under the skin and is given every other week following an initial dose (400 mg and 600 mg, respectively).

Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.

For the treatment of atopic dermatitis, omalizumab has mostly been used in doses ranging from 300 to 450 mg every 2 to 4 weeks (5-7).

The researchers found that the prevalence of atopic dermatitis was 7.3 percent (95 percent confidence interval [CI], 5.9 to 8.8), with 60.1 (95 percent CI, 56.1 to 64.1 percent), 28.9 (95 percent CI, 25.3 to 32.7 percent), and 11 percent (95 percent CI, 8.6 to 13.7 percent) classified as mild, moderate, and severe, respectively.

Results: 84% patients in group A (betamethasone) showed >50% reduction in Scoring of Atopic Dermatitis (SCORAD) whereas 94% patients in group B (NB-UVB) showed >50% reduction in SCORAD (p=0.554).

Recent research into the pathophysiology of atopic dermatitis has yielded two new treatments--the first ones to receive US Food and Drug Administration (FDA) approval for management of this condition in more than a decade.

Canine atopic dermatitis (CAD) is a common, recurring, inflammatory and pruritic allergic skin disease in dogs exhibiting characteristic clinical signs associated with IgE antibodies that is most commonly directed against environmental allergens (Halliwell, 2006).

Cordoro, MD, anyone who cares for patients with severe atopic dermatitis understands the sense of misery that can ensue.